Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).
Krause N, Riemann-Lorenz K, Steffen T, Rahn AC, Pöttgen J, Stellmann JP, Köpke S, Friede T, Icks A, Vomhof M, Temmes H, van de Loo M, Gold SM, Heesen C. Krause N, et al. Among authors: temmes h. BMJ Open. 2021 Feb 16;11(2):e041720. doi: 10.1136/bmjopen-2020-041720. BMJ Open. 2021. PMID: 33593774 Free PMC article.
'That would have been the perfect thing after diagnosis': development of a digital lifestyle management application in multiple sclerosis.
Krause N, Riemann-Lorenz K, Rahn AC, Pöttgen J, Köpke S, Meyer B, Thale F, Temmes H, van de Loo M, Gold SM, Heesen C. Krause N, et al. Among authors: temmes h. Ther Adv Neurol Disord. 2022 Sep 6;15:17562864221118729. doi: 10.1177/17562864221118729. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 36092248 Free PMC article.
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.
Golla H, Dillen K, Hellmich M, Dojan T, Ungeheuer S, Schmalz P, Staß A, Mildenberger V, Goereci Y, Dunkl V, Strupp J, Fink GR, Voltz R, Stock S, Cornely O, Stahmann A, Müller A, Löcherbach P, Burghaus L, Limmroth V, Bonmann E, Gerbershagen K, Nelles G, Joist T, Haas J, Temmes H, Warnke C. Golla H, et al. Among authors: temmes h. BMJ Open. 2022 Jan 25;12(1):e049300. doi: 10.1136/bmjopen-2021-049300. BMJ Open. 2022. PMID: 35078833 Free PMC article.
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.
Frahm N, Fneish F, Ellenberger D, Haas J, Loebermann M, Parciak T, Peters M, Pöhlau D, Rodgers J, Röper AL, Schilling S, Stahmann A, Temmes H, Zettl UK, Middleton RM. Frahm N, et al. Among authors: temmes h. Lancet Reg Health Eur. 2022 Sep 2;22:100502. doi: 10.1016/j.lanepe.2022.100502. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36090519 Free PMC article.
"So at least now I know how to deal with things myself, what I can do if it gets really bad again"-experiences with a long-term cross-sectoral advocacy care and case management for severe multiple sclerosis: a qualitative study.
Müller A, Hebben F, Dillen K, Dunkl V, Goereci Y, Voltz R, Löcherbach P, Warnke C, Golla H; COCOS-MS trial group represented by Martin Hellmich. Müller A, et al. BMC Health Serv Res. 2024 Apr 10;24(1):453. doi: 10.1186/s12913-024-10851-1. BMC Health Serv Res. 2024. PMID: 38600493 Free PMC article.
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.
Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Löbermann M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Fneish F, et al. Among authors: temmes h. Vaccines (Basel). 2023 Dec 16;11(12):1859. doi: 10.3390/vaccines11121859. Vaccines (Basel). 2023. PMID: 38140262 Free PMC article.
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Temmes H, van de Loo M, Friede T, Asendorf T, Heesen C; POWER@MS1 study group. Krause N, et al. Among authors: temmes h. Mult Scler Relat Disord. 2023 Nov;79:105043. doi: 10.1016/j.msard.2023.105043. Epub 2023 Oct 5. Mult Scler Relat Disord. 2023. PMID: 37839367 Free article. Clinical Trial.
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.
Frahm N, Fneish F, Ellenberger D, Haas J, Löbermann M, Peters M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Frahm N, et al. Among authors: temmes h. J Clin Med. 2023 May 24;12(11):3640. doi: 10.3390/jcm12113640. J Clin Med. 2023. PMID: 37297838 Free PMC article.